CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated

Published:2023-04-19 Issue:6 Volume:25 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Kim Hyori¹,Han Mina¹,Kim Minsong¹,Kim Hyeri²,Im Ho Joon²,Kim Nayoung¹,Koh Kyung-Nam²

Affiliation:

1. Department of Convergence Medicine and Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea

2. Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions;Cell Death Discovery;2024-07-10

2. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies;Biological Chemistry;2024-05-21

3. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges;Frontiers in Immunology;2024-04-25

4. Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma;Frontiers in Oncology;2024-04-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP